[en] The relationships between inflammation and cancer are known since the original work by Virchow in the 19th century and have been largely confirmed after-wards. An interesting question is what might be the primum movens. Numerous clinical observations have shown that a chronic inflammatory state, as that observed with some infections, toxic agents or dysimmune diseases, may be associated with the development of cancer later on. Besides, cancer is generally accompanied by an inflammatory microenvironment, with numerous cellular and humoral components, which promotes both tumorigenesis and the invasivity of the tumour. This article aims at defining the pathophysiology of this association, with a description of underlying mechanisms and mediators, and at determining possible therapeutic implications.
Disciplines :
Oncology
Author, co-author :
Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques
Noël, Agnès ; Université de Liège - ULiège > GIGA > GIGA Cancer
Virchow R. Cellular pathology as based upon physiological and pathological histology. Philadelphia: J B Lippincott 1863. 554p.
Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 2021;6:263.
Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;454:436-44.
Heroin L, Uzan J, Nguimpi-Tambou M, et al. Maladies inflammatoires chroniques intestinales et cancers digestifs. Hépato- Gastro & Oncologie Digestive 2019;26:82-95.
Rayburn ER, Ezell SJ, Zhang R. Anti-inflammatory agents for cancer therapy. Mol Cell Pharmacol 2009;1:29-43.
Delvenne P, Renoux VM, Arafa M, et al. Les cancers viroinduits: interrelations génétique-environnement. Rev Med Liege 2012;67:381-9.
Elkoshi Z. Cancer and autoimmune diseases: a tale of two immunological opposites? Front Immunol 2022;13:821598.
Qu YL, Liu J, Zhang LX, et al. Asthma and the risk of lung cancer: a meta-analysis. Oncotarget 2017;8:11614-20.
Qian S, Golubnitschaja O, Zhan X. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. The EPMA J 2019;10:365-81.
Wu B, Sodji QH, Oyelere AK. Inflammation, fibrosis and cancer: mechanisms, therapeutic options and challenges. Cancers (Basel) 2022;14:552.
Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 2019;51:27-41.
Noël A, Gilles C, Sounni NE, et al. Apport du «GIGA-Cancer» de l'ULiège à la recherche sur le microenvironnement tumoral. Rev Med Liege 2021;76:321-26.
Mantovani A, Ponzetta A, Inforzato A, et al. Innate immunity, inflammation and tumour progression: double-edged swords. J Intern Med 2019;285:524-32.
Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 2012;22:33-40.
Kawanishi S, Ohnishi S, Ma N, et al. Crosstalk between DNA damage and inflammation in the multiple steps of carcinogenesis. Int J Mol Sci 2017;18:1808.
Reis ES, Mastellos DC, Ricklin D, et al. Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 2018;18:5-18.
Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6.
Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
Zappavigna S, Cossu AM, Grimaldi A, et al. Anti-inflammatory drugs as anticancer agents. Int J Mol Sci 2020;21:2605.
Todoric J, Antonucci L, Karin M. Targeting inflammation in cancer prevention and therapy. Cancer Prev Res (Phila) 2016;9:895-905.
Scheen AJ. Les médicaments anti-inflammatoires: des anciens classiques aux biothérapies et JAK inhibiteurs. Rev Med Liege 2022;77:sous presse.
Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat Rev Clin Oncol 2021;18:261-79.
Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50.
Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
Wong RS. Role of nonsteroidal anti-inflammatory drugs (NSAIDs) in cancer prevention and cancer promotion. Adv Pharmacol Sci 2019;2019:3418975.
Ritter B, Greten FR. Modulating inflammation for cancer therapy. J Exp Med 2019;216:1234-43.
Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014;15:e493-503.
Lan T, Chen L, Wei X. Inflammatory cytokines in cancer: comprehensive understanding and clinical progress in gene therapy. Cells 2021;10:100.
Kalfeist L, Galland L, Ledys F, et al. Impact of glucocorticoid use in oncology in the immunotherapy era. Cells 2022;11:770.
